Citations

Clear

3942 citation(s) found for "To, Van".

#3330 INFLAMMATION SECONDARY TO CHRONIC KIDNEY DISEASE AND PERITONEAL DIALYSIS ACCELERATES ATHEROSCLEROSIS IN A NEW MOUSE MODEL
Toom, Myrthe den, Vos, Winnie G. , Beckers, Linda, Kane, Jamie, Bosmans, Laura A. , Os, Bram W. van , Jakulj, Lily , Lutgens, Esther , Vervloet, Marc G , Eringa, Etto C.

Mayo Clinic

Nephrology Dialysis Transplantation | June 14, 2023 | Volume: 38 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfad063c_3330 Get It

Abstract Background and Aims Inflammation is an established contributor to accelerated atherosclerosis, which is highly prevalent in people with chronic kidney disease (CKD) and even more so in those treated with peritoneal dialysis (PD). We therefore hypothesised that PD-induced systemic inflammation is essential in the development of atherosclerosis. To study this we developed a novel mouse model of CKD and PD accelerated atherosclerosis. Method We performed a 5/6ths nephrectomy in ApoE deficient “black 6” mice, fed these mice a high-cholesterol diet (HCD), and intraperitoneally administered 3.86% Physioneal daily for 67 days. There were three groups of mice: control (HCD-only), CKD+HCD, and CKD+HCD+PD, with relevant shams. Tissues were harvested twelve weeks after the nephrectomy. Assessments of residual kidney function, atherosclerotic plaque pathology and immunology, and systemic immune responses were performed. Results Atherosclerotic plaque size in the aortic arch was larger in the PD group compared to the control, increasing from 83,779 μm2 ±18,430 to 109,973 μm2 ±25,602 (p = 0.0349), whilst plaque size was unchanged in the CKD group. In contrast, both the CKD and PD groups displayed altered plaque stability. There was less collagen in the plaque vs control, decreasing from 43.54% ±10.65 to 29.71% ±9.43 and 29.73% ±10.18 respectively. Additionally, fibrous cap thickness decreased in both groups vs control. The plaques from only the PD group showed infiltration by T-cells compared to control, with no changes in macrophage content in either the CKD or PD group. In the spleen in the CKD and PD groups, naïve CD4 cells increased and effector CD4 cells decreased compared to control, with the latter change also occurring in the circulation. Central memory CD4 cells, terminally differentiated Th1 cells, Th17 cells, and ‘vascular homing’ cells all increased in the PD group compared to control mice. These homing cells also increased in circulation. The PD group showed decreases in the spleen of regulatory T-cells, effector Th1 cells, and effector CD8 cells. Notably, all of these changes were absent from the mesenteric lymph node. There was a large drop in monocytes in the spleen and a loss of immature and mature dendritic cells in the PD group. Conclusion Combining CKD, a high-cholesterol diet, and exposure to PD fluids in ApoE−/-mice successfully generated a new model for cardiovascular disease in human PD patients. This new model is in a widespread and well-understood mouse line representative of human atherosclerosis. Here we demonstrate the pronounced effects of CKD and PD on the innate and adaptive immune response which increases atherosclerotic burden and leads to larger more vulnerable plaques
The impact of neighborhoods and friendships on interracial anxiety among medical students and residents: A report from the medical student CHANGES study
Plaisime, Marie V. , Jipguep‐Akhtar, Marie, Locascio, Joseph J. , Belcher, Harolyn M. E. , Hardeman, Rachel R. , Picho, Katherine , Perry, Sylvia , Phelan, Sean M. , Ryn, Michelle van , Dovidio, John F. , Picho-Kiroga, Katherine , Perry, Sylvia P , van Ryn, Michelle , Phelan, S M

Mayo Clinic

Health Services Research | June 14, 2023 | Volume: 58 | Issue: S2 | Pages: 229-237

10.1111/1475-6773.14191 | PMID 37312013 Get It

AbstractObjectiveTo examine the experience of interracial anxiety among health professionals and how it may affect the quality of their interactions with patients from racially marginalized populations. We explored the influence of prior interracial exposure—specifically through childhood neighborhoods, college student bodies, and friend groups—on interracial anxiety among medical students and residents. We also examined whether levels of interracial anxiety change from medical school through residency.Data SourceWeb‐based longitudinal survey data from the Medical Student Cognitive Habits and Growth Evaluation Study.Study DesignWe used a retrospective longitudinal design with four observations for each trainee. The study population consisted of non‐Black US medical trainees surveyed in their 1st and 4th years of medical school and 2nd and 3rd years of residency. Mixed effects longitudinal models were used to assess predictors of interracial anxiety and assess changes in interracial anxiety scores over time.Principal FindingsIn total, 3155 non‐Black medical trainees were followed for 7 years. Seventy‐eight percent grew up in predominantly White neighborhoods. Living in predominantly White neighborhoods and having less racially diverse friends were associated with higher levels of interracial anxiety among medical trainees. Trainees' interracial anxiety scores did not substantially change over time; interracial anxiety was highest in the 1st year of medical school, lowest in the 4th year, and increased slightly during residency.ConclusionsNeighborhood and friend group composition had independent effects on interracial anxiety, indicating that premedical racial socialization may affect medical trainees' preparedness to interact effectively with diverse patient populations. Additionally, the lack of substantial change in interracial anxiety throughout medical training suggests the importance of providing curricular tools and structure (e.g., instituting interracial cooperative learning activities) to foster the development of healthy interracial relationships.
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
Schröder, Carolien P., Leeuwen-Stok, Elise van, Poncet, Coralie , Bjelic‐Radisic, Vesna , Abreu, Miguel Henriques, Božović‐Spasojević, Ivana, Hoed, Irma D.M. den, Honkoop, Aafke H. , Los, Maartje , Leone, José Pablo , Russell, Nicola S. , Smilde, Tineke J. , Velden, Annette W.G. van der , Poznak, Catherine Van , Vleugel, M M, Yung, Rachel L. , Coens, Corneel , Ruddy, Kathryn J. , Van Poznak, Catherine , Ruddy, Kathryn J , Cardoso, Fátima , Linderholm, Barbro Kristina , Wolff, Antonio C. , Werutsky, Gustavo , Giordano, Sharon H. , Abreu, M.H.

Mayo Clinic

The Oncologist | June 13, 2023 | Volume: 28 | Issue: 10 | Pages: e877-e883

10.1093/oncolo/oyad152 | PMID 37310797 Get It

Abstract Introduction Prospective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program. Methods Questionnaires at BC diagnosis included the EORTC QLQ-C30 and BR23 (BC specific module), adapted for men. High functioning and global health/QoL scores indicate high functioning levels/high QoL; high symptom-focused measures scores indicate high symptoms/problems levels. EORTC reference data for healthy men and women with BC were used for comparisons. Results Of 422 men consenting to participate, 363 were evaluable. Median age was 67 years, and median time between diagnosis and survey was 1.1 months. A total of 114 men (45%) had node-positive early disease, and 28 (8%) had advanced disease. Baseline mean global health status score was 73 (SD: 21), better than in female BC reference data (62, SD: 25). Common symptoms in male BC were fatigue (22, SD: 24), insomnia (21, SD: 28), and pain (16, SD: 23), for which women’s mean scores indicated more burdensome symptoms at 33 (SD: 26), 30 (SD: 32), and 29 (SD: 29). Men’s mean sexual activity score was 31 (SD: 26), with less sexual activity in older patients or advanced disease. Conclusions QoL and symptom burden in male BC patients appears no worse (and possibly better) than that in female patients. Future analyses on impact of treatment on symptoms and QoL over time, may support tailoring of male BC management.
Concurrent measurement of perfusion parameters related to small blood vessels and cerebrospinal fluid circulation in the human brain using dynamic dual‐spin‐echo perfusion MRI
Cao, Di , Sun, Yuanqi , Li, Yinghao , Pillai, Jay J. , Qiao, Ye , Knutsson, Linda , Sun, Yang-bai , Su, Pan , Knutsson, Linda , Pillai, Jay J , Sun, Yuanqi , Hua, Jun , Lu, Hanzhang , Zijl, Peter C.M. van

Mayo Clinic

NMR in Biomedicine | June 12, 2023 | Volume: 36 | Issue: 10 | Pages: No page available

10.1002/nbm.4984 | PMID 37308297 Get It

AbstractAccumulating evidence from recent studies has indicated the importance of studying the interaction between the microvascular and lymphatic systems in the brain. To date, most imaging methods can only measure blood or lymphatic vessels separately, such as dynamic susceptibility contrast (DSC) MRI for blood vessels and DSC MRI‐in‐the‐cerebrospinal fluid (CSF) (cDSC MRI) for lymphatic vessels. An approach that can measure both blood and lymphatic vessels in a single scan offers advantages such as a halved scan time and contrast dosage. This study attempts to develop one such approach by optimizing a dual‐echo turbo‐spin‐echo sequence, termed “dynamic dual‐spin‐echo perfusion (DDSEP) MRI”. Bloch simulations were performed to optimize the dual‐echo sequence for the measurement of gadolinium (Gd)‐induced blood and CSF signal changes using a short and a long echo time, respectively. The proposed method furnishes a T1‐dominant contrast in CSF and a T2‐dominant contrast in blood. MRI experiments were performed in healthy subjects to evaluate the dual‐echo approach by comparing it with existing separate methods. Based on simulations, the short and long echo time were chosen around the time when blood signals show maximum difference between post‐ and pre‐Gd scans, and the time when blood signals are completely suppressed, respectively. The proposed method showed consistent results in human brains as previous studies using separate methods. Signal changes from small blood vessels occurred faster than from lymphatic vessels after intravenous Gd injection. In conclusion, Gd‐induced signal changes in blood and CSF can be detected simultaneously in healthy subjects with the proposed sequence. The temporal difference in Gd‐induced signal changes from small blood and lymphatic vessels after intravenous Gd injection was confirmed using the proposed approach in the same human subjects. Results from this proof‐of‐concept study will be used to further optimize DDSEP MRI in subsequent studies.
Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy
Preißer, Felix , Incesu, Reha‐Baris , Rajwa, Paweł , Chłosta, Marcin , Ahmed, Mohamed E. , Cacciamani, Giovanni , Kretschmer, Alexander , Westhofen, Thilo , Smith, Joseph A. , Graefen, Markus , Calleris, Giorgio , Raskin, Yannic , Joniau, Steven , Sanchez‐Salas, Rafael , Gill, Inderbir S. , Karnes, R. Jeffrey , Cathcart, Paul, Poel, Henk G. van der , Marra, Giancarlo , Tilki, Derya , Ahmed, Mohamed , Cacciamani, Giovanni E , Kretschmer, Alexander , Calleris, Giorgio , Joniau, Steven , Karnes, Robert Jeffrey, Tilki, Derya , Gill, Inderbir S , Rajwa, Pawel , Marra, Giancarlo , Abreu, Andre Luis , Ribeiro, Luis, Gontero, Paolo , Shariat, Shahrokh F.

Mayo Clinic

Cancers | June 9, 2023 | Volume: 15 | Issue: 12 | Pages: 3123

10.3390/cancers15123123 | PMID 37370733 Get It

Background: Lymph node invasion (LNI) represents a poor prognostic factor after primary radical prostatectomy (RP) for prostate cancer (PCa). However, the impact of LNI on oncologic outcomes in salvage radical prostatectomy (SRP) patients is unknown. Objective: To investigate the impact of lymph node dissection (LND) and pathological lymph node status (pNX vs. pN0 vs. pN1) on long-term oncologic outcomes of SRP patients. Patients and methods: Patients who underwent SRP for recurrent PCa between 2000 and 2021 were identified from 12 high-volume centers. Kaplan–Meier analyses and multivariable Cox regression models were used. Endpoints were biochemical recurrence (BCR), overall survival (OS), and cancer-specific survival (CSS). Results: Of 853 SRP patients, 87% (n = 727) underwent LND, and 21% (n = 151) harbored LNI. The median follow-up was 27 months. The mean number of removed lymph nodes was 13 in the LND cohort. At 72 months after SRP, BCR-free survival was 54% vs. 47% vs. 7.2% for patients with pNX vs. pN0 vs. pN1 (p < 0.001), respectively. At 120 months after SRP, OS rates were 89% vs. 81% vs. 41% (p < 0.001), and CSS rates were 94% vs. 96% vs. 82% (p = 0.02) for patients with pNX vs. pN0 vs. pN1, respectively. In multivariable Cox regression analyses, pN1 status was independently associated with BCR (HR: 1.77, p < 0.001) and death (HR: 2.89, p < 0.001). Conclusions: In SRP patients, LNI represents an independent poor prognostic factor. However, the oncologic benefit of LND in SRP remains debatable. These findings underline the need for a cautious LND indication in SRP patients as well as strict postoperative monitoring of SRP patients with LNI.
International validation of the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score in heart failure
Adamopoulos, Stamatis , Miliopoulos, Dimitrios , Piotrowicz, Ewa , Snoek, Johan A. , Panagopoulou, Niki , Niederseer, David , Mazaheri, Reza , Ma, Jing , Chen, Yundai , Popović, Dejana , Seferović, Petar , Girola, Davide, Metra, Marco , Rosano, Giuseppe , Piepoli, Massimo , Corrà, Ugo , Agostoni, Piergiuseppe , Metra, Marco , Nanas, Serafim , Corrà, Ugo , Coats, Andrew J.S. , Volterrani, Maurizio , Apostolo, Anna , Campodonico, Jeness , Salvioni, Elisabetta

Mayo Clinic

European Journal of Preventive Cardiology | June 8, 2023 | Volume: 30 | Issue: 13 | Pages: 1371-1379

10.1093/eurjpc/zwad191 | PMID 37288595 Get It

Abstract Aims Current European heart failure (HF) guidelines suggest the use of risk score: among them, the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score has demonstrated to be one of the most accurate. However, the risk scores are still poorly implemented in clinical practice, also due to the lack of strong evidence regarding their external validation in different populations. Thus, the current study was designed as an external validation test of the MECKI score in an international multicentre setting. Methods and results The study cohort consisted of patients diagnosed with HF with reduced ejection fraction (HFrEF) across international centres (not Italian), retrospectively recruited. Collected data included demographics, HF aetiology, laboratory testing, electrocardiogram (ECG), echocardiographic findings, and cardiopulmonary exercise testing (CPET) results as described in the original MECKI score publication. A total of 1042 patients across 8 international centres (7 European and 1 Asian) were included and followed up from 1998 till 2019. Patients were divided according to the calculated MECKI scores into three subgroups: (i) MECKI score &lt;10%, (ii) 10–20%, and (iii) ≥ 20%. Survival analysis comparison among the three MECKI score subgroups showed a worse prognosis in patients with higher MECKI score value: median event-free survival times were 4396 days for MECKI score &lt;10%, 3457 days for 10–20%, and 1022 days for ≥20% (P &lt; 0.0001). Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were like those reported in the original internal validation studies. Conclusion In patients diagnosed with HFrEF, the power of the MECKI score was confirmed in terms of prognosis and risk stratification, supporting its implementation as advised by the HF guidelines.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Kelly, Ronan J. , Iyer, Renuka , Kemberling, Holly , Krishnamurthi, Smitha , Mordecai, Mindy Mintz, Paulson, Andrew Scott , Peterson, Valerie, Ku, Geoffrey , Shah, Manish A , Bever, Katherine M. , Chao, Joseph , Ciombor, Kristen K. , Eng, Cathy , Fakih, Marwan , Goyal, Lipika , Hubbard, Joleen M. , Morris, Van K. , Le, Dung Thi

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 7, 2023 | Volume: 11 | Issue: 6 | Pages: e006658

10.1136/jitc-2022-006658 | PMID 37286304 Get It

Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and prolonged survival. Specifically, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1 (PD-1), either as monotherapies or in combination regimens, have gained tissue site-specific regulatory approvals for the treatment of metastatic disease and in the resectable setting. Indications for ICIs in GI cancer, however, have differing biomarker and histology requirements depending on the anatomic site of origin. Furthermore, ICIs are associated with unique toxicity profiles compared with other systemic treatments that have long been the mainstay for GI cancer, such as chemotherapy. With the goal of improving patient care by providing guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of GI cancer. Drawing from published data and clinical experience, the expert panel developed evidence- and consensus-based recommendations for healthcare professionals using ICIs to treat GI cancers, with topics including biomarker testing, therapy selection, and patient education and quality of life considerations, among others.
Trapezoid Avascular Necrosis
Tran, Aaron , Mousa, Abeer, Tassel, Dane C. Van

Mayo Clinic

No container title available | June 5, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20237017 Get It

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
Mandrekar, Sumithra J. , Allred, Jacob B., Hensley, Martee L. , Tine, Brian Andrew Van, Lacuna, Kristine Peregrino , Berg, Stephanie , George, Suzanne , Schwartz, Gary K. , Ingham, Matthew

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: TPS11584-TPS11584

10.1200/jco.2023.41.16_suppl.tps11584 Get It

TPS11584 Background: Uterine leiomyosarcoma (uLMS) is an aggressive sarcoma subtype with frequent metastatic relapse. Advanced uLMS is treated with gemcitabine/docetaxel or anthracycline-based regimens. After failure of initial chemotherapy, remaining options provide limited benefit (trabectedin: objective response rate (ORR) 11%, median progression-free survival (mPFS) 4.0 months (mo); pazopanib: ORR 11%, mPFS 3.0 mo; dacarbazine: ORR 9%, mPFS 1.5 mo). 18-23% of uLMS harbor deleterious alterations in homologous recombination (HR) DNA repair genes. HR-deficient cancers are unable to effectively repair double-stranded DNA breaks and may be sensitive to poly ADP-ribose polymerase (PARP) inhibitor-based strategies. In preclinical studies, the combination of temozolomide (T), an alkylating agent, and olaparib (O), a PARP inhibitor, markedly suppressed proliferation of uLMS models. Among 22 uLMS patients with median 3 prior lines, O+T demonstrated mPFS 6.9 mo and ORR 27% (Ingham M. et al. ASCO 2021: #11506). In correlative analysis, alterations in HR genes including PALB2 and RAD51B or absence of RAD51 foci formation by a functional assay were observed in patients with prolonged PFS (Bose S. et al. ASCO 2022: #11509). Based on these results, we designed a randomized phase 2/3 study to further evaluate O+T in advanced, pretreated uLMS. Methods: Alliance for Clinical Trials in Oncology A092104 is a randomized, open-label phase 2/3 clinical trial of O+T versus investigator’s choice in advanced uLMS. Eligible patients have ECOG performance status ≤2, progression on ≥ 2 prior treatment lines and measurable disease. Patients are randomized 1:1 to receive T 75 mg/m2 orally daily + O 200 mg orally twice daily on days 1-7 in 21-day cycles (Arm 1) or investigator’s choice of trabectedin 1.5 mg/m2 over 24 hours every 21 days or pazopanib 400-600 mg orally daily (Arm 2). For phase 2, the primary endpoint is PFS. The design evaluates for an improvement in PFS from 4 mo to 8 mo, requires 70 patients, and yields 90% power and 1-sided alpha 0.10. If phase 2 is positive, phase 3 will enroll. For phase 3, the primary endpoint is overall survival (OS). The design evaluates for an improvement in OS from 13 mo to 23 mo, requires 165 patients (including 70 from phase 2) and yields 90% power with 1-sided alpha 0.025. Secondary endpoints include ORR, duration of response, safety and patient-reported outcomes. Archival tissue will be collected and evaluated with a RAD51 foci formation assay. Genomic sequencing results will be obtained where available. The study opened to accrual in 1/2023. Support: U10CA180821, U10CA180882, U24 CA196171; https://acknowledgments.alliancefound.org . Clinical trial information: NCT05633381 .
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.
Tine, Brian Andrew Van, Ganjoo, Kristen N. , Araujo, Dejka M. , Razak, Albiruni Ryan Abdul, Cesne, Axel Le , Schuetze, Scott M. , Wagner, Michael J. , Attia, Steven , Forcade, Édouard , Druta, Mihaela , Bai, Jane P. F., Winkle, Erin Van, Norry, Elliot , McAlpine, Cheryl, Williams, Dennis, Blay, Jean‐Yves , Valverde, Claudia María , Pollack, Seth M. , Bayer, Paige , D'Angelo, Sandra P

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 11563-11563

10.1200/jco.2023.41.16_suppl.11563 Get It

11563 Background: Afami-cel is an autologous, T-cell receptor (TCR) T-cell therapy to treat human leukocyte antigen (HLA) A*02–eligible patients (pts) with advanced solid tumors positive for the cancer testis antigen melanoma-associated antigen A4 (MAGE-A4). The efficacy and safety of afami-cel in pretreated pts with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma are being evaluated in the Phase 2, two-cohort, open-label, SPEARHEAD-1 (NCT04044768) trial. Here we report interim overall survival (OS) data in the pts with advanced synovial sarcoma in Cohort 1. Methods: Pts who were HLA-A*02 positive with advanced synovial sarcoma (with evidence of clinical/radiological progression) positive for MAGE-A4 received afami-cel after lymphodepleting chemotherapy containing fludarabine and cyclophosphamide. The primary endpoint was overall response rate per RECIST v1.1 by independent review. Secondary endpoints included OS and progression-free survival (PFS), estimated utilizing the Kaplan-Meier method. Results: As of August 29, 2022, 44 pts with synovial sarcoma received afami-cel (2.68–9.99×109 transduced T-cells) in Cohort 1. The median age was 41 years (range: 19–73 years), 50% of pts were female, 89% of pts were white, 96% of pts were typed as HLA-A*02:01P, and median tumor MAGE-A4 expression H-score was 257 (132–300). Pts were heavily pre-treated with a median of 3 prior lines of therapy (range: 1–12). The median follow-up time at the data cut-off was 20.8 months. Median PFS was 3.8 months (95% CI: 2.8, 5.8) and 4.1 months (95% CI: 2.8, 6.9) by independent and investigator review, respectively. Median OS by independent review was 15.4 months (95% CI: 10.9, not estimable) with 52% of pts censored at the data cut-off. The 12-month OS probability was 60% and 24-month OS probability was 40%. Twenty-one pts received additional therapy during long term follow up (systemic therapy, n = 20; radiation, n = 6; other, n = 4). In the 17 pts who had a RECIST response by independent review, the median OS was not reached, the 12-month OS probability was 90%, and 24-month OS probability was 60%. Conclusions: Pts with advanced synovial sarcoma treated with afami-cel in SPEARHEAD-1 had encouraging survival, especially those pts with a RECIST response. Clinical trial information: NCT04044768 .